Hui-Xia Zheng1, Li-Na Wu1, Hong Xiao1, Qian Du1, Jian-Fang Liang1. 1. Hui-Xia Zheng, Li-Na Wu, Hong Xiao, Qian Du, Jian-Fang Liang, Department of Pathology, The First Hospital, Shanxi Medical University, Taiyuan 030024, Shanxi Province, China.
Abstract
AIM: To explore the inhibitory effects of dobutamine on gastric adenocarcinoma cells. METHODS: Dobutamine was used to treat gastric adenocarcinoma cells (SGC-7901) and cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The effects of dobutamine combined with cisplatin on cell viability were also analyzed. Cell migration was studied using the wound healing assay, and cell proliferation was analyzed using the colony formation assay. A cell invasion assay was carried out using Transwell cell culture chambers. The cell cycle and cell apoptosis were analyzed by flow cytometry. Western blot and immunocytochemistry were performed to determine the expression of Yes-associated protein (YAP) in treated cells. RESULTS: Dobutamine significantly inhibited cell growth, migration, cell colony formation, and cell invasion into Matrigel. Dobutamine also arrested the cell cycle at G1/S phase, and increased the rate of apoptosis of gastric adenocarcinoma cells. The expression of YAP was detected mainly in the nucleus in the absence of dobutamine. However, reduced expression of phosphorylated YAP was mainly found in the cytosol following treatment with dobutamine. CONCLUSION: Dobutamine has significant inhibitory effects on gastric adenocarcinoma cells and may be used in neoadjuvant therapy not only for gastric cancer, but also for other tumors.
AIM: To explore the inhibitory effects of dobutamine on gastric adenocarcinoma cells. METHODS:Dobutamine was used to treat gastric adenocarcinoma cells (SGC-7901) and cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The effects of dobutamine combined with cisplatin on cell viability were also analyzed. Cell migration was studied using the wound healing assay, and cell proliferation was analyzed using the colony formation assay. A cell invasion assay was carried out using Transwell cell culture chambers. The cell cycle and cell apoptosis were analyzed by flow cytometry. Western blot and immunocytochemistry were performed to determine the expression of Yes-associated protein (YAP) in treated cells. RESULTS:Dobutamine significantly inhibited cell growth, migration, cell colony formation, and cell invasion into Matrigel. Dobutamine also arrested the cell cycle at G1/S phase, and increased the rate of apoptosis of gastric adenocarcinoma cells. The expression of YAP was detected mainly in the nucleus in the absence of dobutamine. However, reduced expression of phosphorylated YAP was mainly found in the cytosol following treatment with dobutamine. CONCLUSION:Dobutamine has significant inhibitory effects on gastric adenocarcinoma cells and may be used in neoadjuvant therapy not only for gastric cancer, but also for other tumors.
Entities:
Keywords:
Dobutamine; Gastric adenocarcinoma cells; Hippo pathway; Human gastric adenocarcinoma cell line SGC-7901; Therapy; Yes-associated protein
Authors: Daniëlle Robbers-Visser; Saskia E Luijnenburg; Jochem van den Berg; Jolien W Roos-Hesselink; Jan L Strengers; Livia Kapusta; Adriaan Moelker; Willem A Helbing Journal: Int J Cardiol Date: 2009-09-09 Impact factor: 4.164
Authors: Tsutomu Oka; Eline Remue; Kris Meerschaert; Berlinda Vanloo; Ciska Boucherie; David Gfeller; Gary D Bader; Sachdev S Sidhu; Joël Vandekerckhove; Jan Gettemans; Marius Sudol Journal: Biochem J Date: 2010-12-15 Impact factor: 3.857
Authors: Angela A Steinhardt; Mariana F Gayyed; Alison P Klein; Jixin Dong; Anirban Maitra; Duojia Pan; Elizabeth A Montgomery; Robert A Anders Journal: Hum Pathol Date: 2008-08-13 Impact factor: 3.466
Authors: Niamat Ali Khan; Nicolas Willemarck; Ali Talebi; Arnaud Marchand; Maria Mercedes Binda; Jonas Dehairs; Natalia Rueda-Rincon; Veerle W Daniels; Muralidhararao Bagadi; Deepak Balaji Thimiri Govinda Raj; Frank Vanderhoydonc; Sebastian Munck; Patrick Chaltin; Johannes V Swinnen Journal: Oncotarget Date: 2016-03-01
Authors: Luo Yuan Yuan; Wu Shuai; Zou Yuan-Peng; Jiang Ting; Xia Wei; He Yu-Qin Journal: Evid Based Complement Alternat Med Date: 2022-07-19 Impact factor: 2.650
Authors: Jun Ma; Jenny Wang; Laleh Soltan Ghoraie; Xin Men; Benjamin Haibe-Kains; Penggao Dai Journal: Front Pharmacol Date: 2019-02-19 Impact factor: 5.810